Omega Healthcare Investors Inc. Common Stock (OHI)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable cash flows bought at a sensible price. Omega owns skilled-nursing and assisted-living real estate, mostly triple-net leased to many operators in the US, UK and Canada. The 69-employee structure means it is a landlord, not a caregiver. The moat is modest: long leases and scale help, but reimbursement, labor and operator credit drive results. Financial data are mixed. For FY2025, filed revenue was $1.2B, net income $590.2M, diluted EPS $1.94, up from FY2024 revenue $1.1B, net income $406.3M, EPS $1.55, and FY2023 revenue $949.7M, net income $242.2M, EPS $1.00. That is real profit improvement. But REIT EPS and P/E of 16.09 are distorted by depreciation; FFO/AFFO, the proper measures, are not in the data, so I lean on dividend yield, leverage, revenue trend and price-to-book. The 5.83% dividend yield and 6.5% FCF yield are attractive if sustainable. Debt/equity of 0.71 and Altman Z-Score of 1.70 warrant caution; ROCE 4.91% is low. P/B of 2.51 is not a book-value bargain. At $45.22, below the $52.39 52-week high, the price looks fair, not distressed. FairStock's Lynch label is STALWART, based on 29.3% five-year profit growth and 5.9% revenue growth. I would want FFO/AFFO coverage before calling it comfortable.

In plain English: Omega owns nursing homes and assisted-living buildings and leases them to healthcare operators. The business is profitable and pays a high dividend, but it carries meaningful debt and its profits can be uneven. At $45.22, the price looks moderate—neither a clear bargain nor obviously overpriced—compared with its earnings and property value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer